EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSPPRG00000009535
Gene Symbol: PIK3CD
4 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSPPRG00000006142
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSPPRG00000012201
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSPPRG00000000622
Gene Symbol: PDE3A
3 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSPPRG00000000697
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSPPRG00000023496
Gene Symbol: PDE4A
4 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSPPRG00000011824
Gene Symbol: PDE4B
4 Cross references
292 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSPPRG00000004111
Gene Symbol: PDE4C
3 Cross references
269 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSPPRG00000013829
Gene Symbol: PDE4D
4 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSPPRG00000002118
Gene Symbol: PDE5A
4 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSPPRG00000008150
Gene Symbol: PDE7A
4 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPPRG00000024077
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).